A Challenging Case of Severe Ulcerative Colitis following the Initiation of Secukinumab for Ankylosing Spondylitis

A Challenging Case of Severe Ulcerative Colitis following the Initiation of Secukinumab for Ankylosing Spondylitis

Secukinumab is an interleukin-17 inhibitor used for the treatment of ankylosing spondylitis (AS), psoriasis, and psoriatic arthritis. The risk of exacerbating underlying inflammatory bowel disease (IBD) in patients being treated with secukinumab for other conditions is controversial. We document a p...

Full description

Bibliographic Details
Main Authors: Dean Ehrlich, Nimah Jamaluddin, Joseph Pisegna, David Padua
Format: Article
Language:English
Published: Hindawi Limited 2018-01-01
Series:Case Reports in Gastrointestinal Medicine
Online Access:http://dx.doi.org/10.1155/2018/9679287
id doaj-2b53b2c3b9a84a91a15ecc71563b3191
record_format Article
spelling doaj-2b53b2c3b9a84a91a15ecc71563b31912020-11-25T00:24:46ZengHindawi LimitedCase Reports in Gastrointestinal Medicine2090-65282090-65362018-01-01201810.1155/2018/96792879679287A Challenging Case of Severe Ulcerative Colitis following the Initiation of Secukinumab for Ankylosing SpondylitisDean Ehrlich0Nimah Jamaluddin1Joseph Pisegna2David Padua3Division of Digestive Diseases, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USADivision of Digestive Diseases, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USADivision of Digestive Diseases, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USADivision of Digestive Diseases, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USASecukinumab is an interleukin-17 inhibitor used for the treatment of ankylosing spondylitis (AS), psoriasis, and psoriatic arthritis. The risk of exacerbating underlying inflammatory bowel disease (IBD) in patients being treated with secukinumab for other conditions is controversial. We document a patient with AS and previously undiagnosed IBD, found to be in a severe ulcerative colitis flare shortly after receiving the loading dose of secukinumab. There are no guidelines regarding biologic salvage therapy for IBD in the setting of active treatment with another biologic agent. After waiting one half-life of secukinumab, our patient had an excellent response to initiation of infliximab.http://dx.doi.org/10.1155/2018/9679287
collection DOAJ
language English
format Article
sources DOAJ
author Dean Ehrlich
Nimah Jamaluddin
Joseph Pisegna
David Padua
spellingShingle Dean Ehrlich
Nimah Jamaluddin
Joseph Pisegna
David Padua
A Challenging Case of Severe Ulcerative Colitis following the Initiation of Secukinumab for Ankylosing Spondylitis
Case Reports in Gastrointestinal Medicine
author_facet Dean Ehrlich
Nimah Jamaluddin
Joseph Pisegna
David Padua
author_sort Dean Ehrlich
title A Challenging Case of Severe Ulcerative Colitis following the Initiation of Secukinumab for Ankylosing Spondylitis
title_short A Challenging Case of Severe Ulcerative Colitis following the Initiation of Secukinumab for Ankylosing Spondylitis
title_full A Challenging Case of Severe Ulcerative Colitis following the Initiation of Secukinumab for Ankylosing Spondylitis
title_fullStr A Challenging Case of Severe Ulcerative Colitis following the Initiation of Secukinumab for Ankylosing Spondylitis
title_full_unstemmed A Challenging Case of Severe Ulcerative Colitis following the Initiation of Secukinumab for Ankylosing Spondylitis
title_sort challenging case of severe ulcerative colitis following the initiation of secukinumab for ankylosing spondylitis
publisher Hindawi Limited
series Case Reports in Gastrointestinal Medicine
issn 2090-6528
2090-6536
publishDate 2018-01-01
description Secukinumab is an interleukin-17 inhibitor used for the treatment of ankylosing spondylitis (AS), psoriasis, and psoriatic arthritis. The risk of exacerbating underlying inflammatory bowel disease (IBD) in patients being treated with secukinumab for other conditions is controversial. We document a patient with AS and previously undiagnosed IBD, found to be in a severe ulcerative colitis flare shortly after receiving the loading dose of secukinumab. There are no guidelines regarding biologic salvage therapy for IBD in the setting of active treatment with another biologic agent. After waiting one half-life of secukinumab, our patient had an excellent response to initiation of infliximab.
url http://dx.doi.org/10.1155/2018/9679287
work_keys_str_mv AT deanehrlich achallengingcaseofsevereulcerativecolitisfollowingtheinitiationofsecukinumabforankylosingspondylitis
AT nimahjamaluddin achallengingcaseofsevereulcerativecolitisfollowingtheinitiationofsecukinumabforankylosingspondylitis
AT josephpisegna achallengingcaseofsevereulcerativecolitisfollowingtheinitiationofsecukinumabforankylosingspondylitis
AT davidpadua achallengingcaseofsevereulcerativecolitisfollowingtheinitiationofsecukinumabforankylosingspondylitis
AT deanehrlich challengingcaseofsevereulcerativecolitisfollowingtheinitiationofsecukinumabforankylosingspondylitis
AT nimahjamaluddin challengingcaseofsevereulcerativecolitisfollowingtheinitiationofsecukinumabforankylosingspondylitis
AT josephpisegna challengingcaseofsevereulcerativecolitisfollowingtheinitiationofsecukinumabforankylosingspondylitis
AT davidpadua challengingcaseofsevereulcerativecolitisfollowingtheinitiationofsecukinumabforankylosingspondylitis
_version_ 1725351767682580480

Similar Items